Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026807 | 0.87 | CA2 (0.70) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL1982061 | 0.85 | TSHR (0.52) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL19420438 | 0.84 | CYP2C19 (0.49) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL906817 | 0.82 | CA2 (0.57) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL27783325 | 0.82 | CA2 (0.57) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL4627288 | 0.82 | CA2 (0.57) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL7018792 | 0.81 | CA2 (0.60) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL14583060 | 0.80 | CYP3A4 (0.48) | CA2CA1CYP2C19SMN1; SMN2TSHR | |
| SCHEMBL20710745 | 0.79 | CA1 (0.62) | CA2CA1BCHEACHEMEN1 | |
| SCHEMBL3294100 | 0.79 | TSHR (0.69) | CA2CA1BCHEACHEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117820636-B | Enzyme-responsive cytotoxic polyamino acid, and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2024-05-24 | — | — | CN | claimed |
| CN-117820636-A | Enzyme-responsive cytotoxic polyamino acid, and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2024-04-05 | — | — | CN | claimed |
| WO-2025043219-A1 | METHODS FOR UNCAGING TETRAZINES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-27 | — | — | WO | disclosed |
| EP-3773563-B1 | PRODRUGS OF FUSED-BICYCLIC C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-117820636-B | Enzyme-responsive cytotoxic polyamino acid, and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2024-05-24 | — | — | CN | disclosed |
| CN-117820636-A | Enzyme-responsive cytotoxic polyamino acid, and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2024-04-05 | — | — | CN | disclosed |
| CN-111954525-B | Prodrugs of fused bicyclic C5aR antagonists | 凯莫森特里克斯股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-11608336-B2 | Prodrugs of fused-bicyclic C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| CN-110606859-B | Aggregation-induced emission compound, preparation method thereof and application thereof in virus detection | 香港科技大学 | 2022-11-22 | — | — | CN | disclosed |
| CN-109310686-B | Soluble C5aR antagonists | 凯莫森特里克斯股份有限公司 | 2022-06-21 | — | — | CN | disclosed |
| US-20210052612-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20080299593-A1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | PROMEGA CORPORATION (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080299593-A1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | PROMEGA CORPORATION (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080299593-A1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | PROMEGA CORPORATION (US) | 2008-12-04 | — | — | US | disclosed |
| EP-1935986-A2 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | PROMEGA CORPORATION (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1885875-A2 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | PROMEGA CORPORATION (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20070015790-A1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2007-01-18 | — | — | US | disclosed |
| US-20070015790-A1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2007-01-18 | — | — | US | disclosed |
| US-20070015790-A1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2007-01-18 | — | — | US | disclosed |
| WO-2006130551-A2 | LUMINOGENIC AND FLUOROGENIC COMPOUNDS AND METHODS TO DETECT MOLECULES OR CONDITIONS | PROMEGA CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11608336-B2 | Prodrugs of fused-bicyclic C5aR antagonists | C5AR2, C5AR1, C3AR1 | CA2 1784/4885CA1 2134/4885BCHE 759/4885 |
| US-20080299593-A1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | GLB1, NOD1, PYCARD | CA2 1062/4885CA1 1484/4885BCHE 2660/4885 |
| US-20210052612-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | C5AR2, C5AR1, C3AR1 | CA2 1784/4885CA1 2134/4885BCHE 759/4885 |
| US-20070015790-A1 | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions | GLB1, NOD1, PYCARD | CA2 1981/4885CA1 2019/4885BCHE 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.